IMPACT Therapeutics, Inc. has circulated a proxy form ahead of its 2025 Annual General Meeting, scheduled for 10:00 a.m. on Thursday, 25 June 2026, at the Board Room, 27F, New Bund Times Square, 399 West Haiyang Road, Pudong District, Shanghai.

Key matters for shareholder approval:

1. 2025 Operating Review • The Board’s 2025 work report will be presented for consideration. • The audited accountant’s report for the financial year ended 31 December 2025 is up for approval.

2. Profit Distribution • A 2025 profit distribution plan will be submitted to shareholders. Specific payout details were not disclosed in the proxy.

3. Auditor Continuation • Re-appointment of the Company’s auditor for the 2026 financial year, with the Board authorised to determine remuneration.

4. Articles of Association Amendment (Special Resolution) • Proposed revisions to the Company’s Articles of Association to be voted on by shareholders.

5. Capital Management Mandates (Special Resolutions) • A general mandate empowering the Board to issue additional shares. • A separate mandate authorising the Board to repurchase H shares.

Procedural Notes • Shareholders may appoint the AGM chairman or another proxy to vote. • Proxy forms and any supporting authorisations must reach Computershare Hong Kong Investor Services by 10:00 a.m. on 24 June 2026. • Identity documentation is required for in-person attendance.

The resolutions, if approved, will guide IMPACT Therapeutics’ governance, capital management and financial reporting framework for the 2026 fiscal year.